Published March 2026

Suboxone vs. Methadone: Why the Film Formulation Causes Dental Damage

One of the most important facts in the Suboxone dental injury litigation is this: the dental damage problem is specific to the film formulation. Methadone — another opioid treatment medication — does not cause the same pattern of dental injury. Neither does Suboxone in tablet form. The problem is the acidic sublingual film, and the manufacturer chose this formulation while failing to warn about its dental consequences.

What Suboxone Film Is — and What Makes It Different

Suboxone comes in several forms. The sublingual film (thin strips that dissolve under or on the tongue) is the most common form prescribed today. The film contains buprenorphine and naloxone in a polymer matrix designed to slowly dissolve over 5–15 minutes, during which time the medication is absorbed through the mucous membranes of the mouth.

The film's pH is approximately 3.4 — highly acidic. This acidity is a function of the film's polymer matrix and preservatives, not of the active medication itself. Buprenorphine in tablet form does not create the same acid exposure.

Why Methadone Doesn't Cause the Same Problem

Methadone, used in methadone maintenance treatment (MMT) for opioid use disorder, is typically administered as an oral liquid or tablet that is swallowed. It does not sit in prolonged contact with tooth surfaces the way Suboxone film does. While methadone can cause dry mouth (which increases dental risk over time), it does not directly apply acid to tooth enamel with every dose.

Methadone's dental risks are real but different in kind: they are largely secondary effects from dry mouth and reduced saliva production. The Suboxone film dental problem is primary — the film itself is acidic and sits on tooth surfaces for minutes at a time, multiple times per day, every day the patient takes the medication.

Why the Film Formulation Exists — and Why It Matters Legally

Suboxone film was introduced in 2010, several years after the original Suboxone tablet. Indivior marketed the film as an improvement — more convenient, more discreet, and harder to misuse than tablets. The film also had the advantage of being reformulation-patent-protected, extending Indivior's market exclusivity after generic tablets became available.

The formulation choice — a highly acidic film designed for oral dissolution — was a business and engineering decision made by the manufacturer. The dental consequences of that formulation decision were either known or knowable from the drug's chemistry. The allegation in the litigation is that Indivior knew about dental adverse events, failed to conduct adequate post-market safety studies, and failed to warn patients — all to protect market share in the film product.

Alternative Formulations — Did Patients Have a Choice?

Patients prescribed Suboxone film typically were not offered a detailed comparison of formulation-specific risks. Prescribers, most of whom are addiction medicine specialists and not dentists, were not educated about the film's acidity or its dental consequences. Generic buprenorphine tablets were available as an alternative, but many patients were prescribed the film as the default without discussion of dental risks.

Patients who would have chosen a different formulation — or who would have taken more protective measures — had they known about the dental risks, have grounds for a failure-to-warn claim even if they are still using Suboxone (in a different form) today.

The Legal Significance of Formulation-Specificity

The fact that the dental injury problem is specific to the film formulation strengthens the litigation. It demonstrates that:

• The injury mechanism is the product design, not general medication side effects
• Alternative designs existed that did not carry the same dental risk
• The manufacturer made a choice that created a foreseeable risk
• A warning label could and should have been included from the outset

These are the elements of a product liability defective design or failure-to-warn claim. The film vs. tablet distinction is one reason the Suboxone dental injury litigation is proceeding against the film manufacturers specifically.